跳至主要内容
临床试验/NCT06029569
NCT06029569尚未招募不适用

Prospective, Multicenter, Randomized Controlled Clinical Trial to Evaluate the Efficacy and Safety of Rapamycin Coated Balloon Dilation Catheter in the Treatment of Dialysis Pathway Stenosis or Blockage in Hemodialysis Patients

Shanghai Bomaian Medical Technology Co., Ltd0 个研究点目标入组 256 人开始时间: 2023年9月15日最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
入组人数
256
主要终点
6-month target lesion primary patency rate

研究概览

简要总结

Verify the effectiveness and safety of rapamycin coated balloon dilation catheter for the treatment of dialysis pathway stenosis or blockage lesions.

详细描述

To verify the effectiveness and safety of the Rapamycin coated arteriovenous fistula balloon dilation catheter developed and produced by Shanghai Bomaian Medical Technology Co., Ltd. in the treatment of stenosis or blockage of the dialysis pathway of autologous arteriovenous fistula in hemodialysis patients.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • AVF has been established, with mature development and at least one successful completion of hemodialysis;
  • AVF has significant hemodynamic abnormalities;
  • exclusion criteria
  • The target lesion has undergone intervention treatment within 30 days;
  • An intravascular stent has been placed at any location along the vascular pathway;

排除标准

  • 未提供

结局指标

主要结局

6-month target lesion primary patency rate

时间窗: 6months

Primary patency is defined as puncture dialysis that can be used to meet the requirements of the dialysis prescription without intervention treatment after the target lesion surgery.

次要结局

  • Surgical success rate(7Days)
  • Device success rate(The day of operation.)
  • Clinical success rate(1year)

研究者

申办方类型
Industry
责任方
Sponsor

相似试验